LXRX Stock Analysis: Buy, Sell, or Hold?
LXRX - Lexicon Pharmaceuticals, Inc.
$2.32
-0.02 (-0.85%)
▼
5d:
+1.31%
30d:
+22.75%
90d:
+41.46%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Smart Money Accumulation
None View Scanner →
Strength: 5.6/10
Get Alerted When LXRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: LXRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: LXRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: LXRX is currently trading at $2.32, which is considered extended relative to its 30-day fair value range of $1.89 to $2.31.
Technical Outlook: Technically, LXRX is in a strong uptrend. Immediate support is located at $1.98, while resistance sits at $2.68.
Market Sentiment: LXRX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $3.77 (+62.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LXRX is in a strong uptrend. Immediate support is located at $1.98, while resistance sits at $2.68.
Market Sentiment: LXRX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $3.77 (+62.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.89 -
$2.31
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 62.5% below Wall St target ($3.77)
Trading Range Analysis
30-Day Trading Range
$1.89 -
$2.31
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.98
Resistance Level
$2.68
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.25
Wall Street Target
$3.77
(+62.5%)
Revenue Growth (YoY)
1572.1%
Earnings Growth (YoY)
-63.4%
Profit Margin
-37.5%
Share & Embed Analysis
Last updated: July 04, 2026 11:13 AM ET
Data refreshes hourly during market hours. Next update: 12:13 PM
Data refreshes hourly during market hours. Next update: 12:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LXRX showing a specific setup today?
Insider Activity (6 Months)
5
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Raymond Debbane
BUY
2000 shares
2026-02-25
Raymond Debbane
BUY
100000 shares
2026-02-23
Raymond Debbane
BUY
100000 shares
2026-02-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 59 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$110 | 61 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 57 HOLD |
|
VERA
Vera Therapeutics Inc |
STRONG BUY
14 analysts |
$78 | 59 HOLD |